MX2009007015A - Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide. - Google Patents

Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide.

Info

Publication number
MX2009007015A
MX2009007015A MX2009007015A MX2009007015A MX2009007015A MX 2009007015 A MX2009007015 A MX 2009007015A MX 2009007015 A MX2009007015 A MX 2009007015A MX 2009007015 A MX2009007015 A MX 2009007015A MX 2009007015 A MX2009007015 A MX 2009007015A
Authority
MX
Mexico
Prior art keywords
methylene
hydroxy
acid
dihydroxyvitamin
retinoyl
Prior art date
Application number
MX2009007015A
Other languages
English (en)
Inventor
Margaret Clagett-Dame
Lori A Plum
Hector F Deluca
Rafal Barycki
Nirca J Nieves
Mary E Kaiser
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MX2009007015A publication Critical patent/MX2009007015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

Se describen las composiciones farmacéuticas orales y tópicas, los kits y métodos de tratamiento de los mismos para tratar diversos trastornos de la piel que incluyen acné, psoriasis, ictiosis, fotoenvejecimiento, piel fotodañada y cáncer de piel. Los análogos de vitamina D ejemplares como ingredientes farmacéuticos activos incluyen 2-metilen-19-nor-20(S)-1a-hidroxi-b ishomopregnacalciferol, 19-nor-26,27-dimetilen-20(S)-2-metilen-1a, 25-dihidroxivitamina D3, 2-metilen-1a,25-dihidroxi-(17E)-17(20)-de shidro-19-nor-vitamina D3, 2-metilen-19-nor-(24R)-1a,25-dihidroxiv itamina D2, 2-metilen-(20R,25S)-19,26-dinor-1a,25-dihidroxivitamin a D3, 2-metilen-19-nor-1a-hidroxi-pregnacalciferol, 1a-hidroxi-2-metilen-19-nor-homopregnacalciferol, (20R)-1-a-hidroxi-2-metilen-19-nor-bishomopregnacalciferol, 2-metilen-19-nor-(20S)-1a-hidroxi-trihomopregnacalciferol, 2-metilen-23,23-difluoro-1a-hidroxi-19-nor-bishomopregnacalcifero l, (2-(3'hidroxipropil-1',2'-iden)-19,23,24-trinor-(20S)-1a-hidrox ivitamina D3, un estereoisómero de los mismos, un profármaco de los mismos en composiciones orales, una sal de los mismos, y/o un soluto de los mismos. Los compuestos que activan los receptores del ácido retinoico, tales como los retinoilos y los ésteres de retinoilo, incluyen el ácido 13-cis-retinoico, ácido todo-trans-retinoico, ácido (2E,4E,6Z,8E)-3,7-dimetil-9-(2,6,6-tri metil-1-ciclohexenil)nona-2,4,6,8-tetranoico, ácido 9-(4-metoxi-2,3,6-trimetil-fenil)-3,7-dimetil-nona-2,4,6,8-tetrae noico, ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftoico, ácido 4-[1-(3,5,5,8,8-pentametil-tetralin-2-il)etenil]benzoico, ácido retinobenzoico, 6-[2-(4,4-dimetiltiocroman-6-il)etinil]piridin-3-c arboxilato, t-butirato de retinoilo, retinoil-pinacol, retinoil-colesterol, un isómero de los mismos, un profármaco de los mismos para composiciones orales, un éster de los mismos, una sal de los mismos, y/o, un soluto de los mismos. Las combinaciones de tales ingredientes activos demuestran eficacia sinérgica.
MX2009007015A 2006-12-29 2007-12-31 Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide. MX2009007015A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88270506P 2006-12-29 2006-12-29
US1721707P 2007-12-28 2007-12-28
US1721907P 2007-12-28 2007-12-28
US11/966,504 US8404667B2 (en) 2006-12-29 2007-12-28 Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
PCT/US2007/089193 WO2008083370A2 (en) 2006-12-29 2007-12-31 Compounds, compostions, kits and methods of use to orally and topically treat acne and other skin conditions by adminstering a 19-nor containing vitamin d analog with or without a reyinoid

Publications (1)

Publication Number Publication Date
MX2009007015A true MX2009007015A (es) 2009-07-09

Family

ID=39446431

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009007015A MX2009007015A (es) 2006-12-29 2007-12-31 Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide.
MX2011000850A MX353142B (es) 2006-12-29 2007-12-31 Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000850A MX353142B (es) 2006-12-29 2007-12-31 Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide.

Country Status (7)

Country Link
US (5) US8404667B2 (es)
EP (2) EP2101727B1 (es)
JP (1) JP5840348B2 (es)
CA (1) CA2674063C (es)
MX (2) MX2009007015A (es)
NZ (1) NZ577962A (es)
WO (1) WO2008083370A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915242B2 (en) * 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
US7947666B2 (en) 2007-12-28 2011-05-24 Wisconsin Alumni Research Foundation 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs
US8609643B2 (en) * 2007-12-28 2013-12-17 Wisconsin Alumni Research Foundation 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs
CA2710954C (en) * 2007-12-28 2015-07-21 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
EP2262507A1 (en) * 2008-03-06 2010-12-22 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
CN101569617A (zh) * 2009-06-11 2009-11-04 辽宁利锋科技开发有限公司 具有金刚烷结构药物及其衍生物和类似物抗肿瘤新适应症的应用
CN102070481A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物曲金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
WO2012166938A2 (en) 2011-06-03 2012-12-06 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
US8940916B2 (en) * 2012-05-30 2015-01-27 Wisconsin Alumni Research Foundation Crystallization of (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3
US9416102B2 (en) 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
JP2016518342A (ja) 2013-03-15 2016-06-23 アヴィセンナ・コスメティクス・エルエルシーAvisenna Cosmetics, Llc 加齢の影響を軽減するための局所組成物
US11497714B2 (en) 2020-10-06 2022-11-15 Sadat A. Al Ali Nano-carrier topical composition with vitamin D3

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1721907A (en) 1927-10-10 1929-07-23 Dura Co Window-regulator mechanism
US1721707A (en) 1928-03-19 1929-07-23 Edward C Miller Weather strip
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4487782A (en) * 1982-03-26 1984-12-11 Ortho Pharmaceutical Corporation Topical treatment of non-inflammatory acne
US4757140A (en) 1986-06-02 1988-07-12 Wisconsin Alumni Research Foundation Coenzyme a derivatives of all-trans- and 13-cis retionic acid
US4841038A (en) 1986-06-02 1989-06-20 Wisconsin Alumni Research Foundation Method for preparing coenzyme a esters of all-trans- and 13-cis retinoic acids
USRE34075E (en) * 1987-06-29 1992-09-22 Molecular Design International, Inc. Dermal uses of trans-retinoids for the treatment of cancer
US4966965A (en) 1988-05-05 1990-10-30 Wisconsin Alumni Research Foundation Method for preparing all-trans retinoyl CoA
US5401731A (en) 1989-06-29 1995-03-28 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) Vitamin D analogues
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5362719A (en) 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
GB9214202D0 (en) 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
GB9223061D0 (en) 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
TW267161B (es) 1992-11-20 1996-01-01 Hoffmann La Roche
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
CA2175881A1 (en) 1995-05-09 1996-11-10 Andrzej Kutner Vitamin d compounds and methods of preparing these compounds
US6221911B1 (en) 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US5808120A (en) 1995-08-22 1998-09-15 Wisconsin Alumni Research Foundation Method of synthesis of retinoic acid
US5998393A (en) 1996-04-05 1999-12-07 Kang; Sewon Methods for assessing 1,25(OH)2 D3 activity in skin and for enhancing the therapeutic use of 1,25(OH)2 D3
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
DK0884308T3 (da) 1997-05-02 2003-07-21 Duphar Int Res Fremgangsmåde til at fremstille 16-dehydro vitamin D forbindelser
WO1998052574A1 (en) 1997-05-22 1998-11-26 Cephalon, Inc. Vitamin d analogues and their neuronal effects
US5880292A (en) 1997-09-11 1999-03-09 Wisconsin Alumni Research Foundation All-trans-retinol metabolite
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US20010002396A1 (en) * 1998-07-16 2001-05-31 Charles Achkar Compositions and methods of treating skin conditions
PT2455083E (pt) 1999-04-23 2013-10-09 Leo Pharma As Composição farmacêutica para aplicação dérmica compreendendo calcipotriol e betametasona para o tratamento da psoríase
US6331642B1 (en) 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs
PL364698A1 (en) 1999-08-04 2004-12-13 Leo Pharmaceutical Products Ltd.A/S (Loopharma A/S) Novel vitamin d analogues
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
US6558656B2 (en) 2000-04-20 2003-05-06 Morris Mann Oral and topical compositions and methods related thereto in the treatment of acne
JP4022141B2 (ja) * 2000-05-31 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−エチル及び２−エチリデン−１９−ノル−ビタミンｄ化合物
ATE273709T1 (de) 2000-09-08 2004-09-15 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor- homopregnacalciferol und seine therapeutische verwendungen
MXPA03003511A (es) 2000-10-27 2004-05-04 Leo Pharma As Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide.
US6924400B2 (en) * 2001-12-10 2005-08-02 Galderma Research & Development, Snc Triaromatic vitamin D analogues
CA2468833C (en) * 2001-12-13 2009-09-08 Wisconsin Alumni Research Foundation (20s)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
ES2276062T3 (es) 2002-03-29 2007-06-16 Wisconsin Alumni Research Foundation Metodo para sintetizar 1-alfa-hidroxi-2-metilen-19-nor-homopregnacalciferol.
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
JP4620472B2 (ja) 2002-08-27 2011-01-26 ガルデルマ・リサーチ・アンド・デヴェロップメント ビタミンｄの類似体
US7566696B2 (en) 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
JP2005020400A (ja) 2003-06-26 2005-01-20 Hitachi Communication Technologies Ltd 無線基地局、無線通信システム、無線基地局の通信制御方法、および、無線通信網の構築方法
WO2004065358A2 (en) 2003-01-17 2004-08-05 Wisconsin Alumni Research Foundation Method of reducing toxicity of retinoids
CA2525987A1 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
JP5009617B2 (ja) 2003-08-20 2012-08-22 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−ビタミンｄ２化合物
CA2544502A1 (en) 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
JP2007512371A (ja) * 2003-11-25 2007-05-17 デルタノイド ファーマシューティカルズ，インコーポレイティド ビタミン化合物を用いる体脂肪の減少方法
JP2008520709A (ja) 2004-11-22 2008-06-19 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−トリスホモプレグナカルシフェロール
MX2007006542A (es) 2004-11-22 2007-07-25 Wisconsin Alumni Res Found 2a-metil-19-nor-(20s)-1a-hidroxi-bishomopregnacalciferol y sus usos.
EP1828113B1 (en) * 2004-11-22 2010-05-12 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
CA2588410C (en) 2004-11-22 2013-04-02 Wisconsin Alumni Research Foundation 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses
EP1831161B1 (en) 2004-11-22 2017-07-26 Wisconsin Alumni Research Foundation Medical and cosmetic uses of 2-methylene-19-nor-(20r)-1-alpha-hydroxy-bishomopregnacalciferol
JP2008530121A (ja) 2005-02-14 2008-08-07 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 多発性硬化症を治療および予防するためのカルシトニンおよびカルシトニン様ペプチド類の使用
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
AU2007235386A1 (en) 2006-04-05 2007-10-18 Wisconsin Alumni Research Foundation 1.Alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and use thereof
EP2004597B1 (en) * 2006-04-10 2011-01-26 Wisconsin Alumni Research Foundation 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds with a 1,1-dimethylpropyl side chain
MX2009002337A (es) 2006-08-29 2009-03-20 Teva Pharma Composiciones farmacologicamente estables que incluyen compuestos que contienen vitamina d y corticosteroides con compatibilidad con bajo ph.
JP5444212B2 (ja) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
US20100144684A1 (en) 2007-04-25 2010-06-10 Proventiv Therapeutics, Inc. Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
WO2009026473A2 (en) 2007-08-21 2009-02-26 Hollis-Eden Pharmaceuticals, Inc. Stabilized therapeutic compositions and formulations
CA2710954C (en) * 2007-12-28 2015-07-21 Wisconsin Alumni Research Foundation (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
EP2237837B1 (en) * 2007-12-28 2012-08-22 Wisconsin Alumni Research Foundation (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
KR20100126376A (ko) 2008-02-13 2010-12-01 디에스엠 아이피 어셋츠 비.브이. 골 무기질 밀도를 개선시키고 골다공증을 치료하기 위한 25-하이드록시-비타민 ｄ3과 비타민 ｄ3의 조합된 용도
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs

Also Published As

Publication number Publication date
WO2008083370A2 (en) 2008-07-10
MX353142B (es) 2017-12-20
US20140018332A1 (en) 2014-01-16
WO2008083370A3 (en) 2009-06-18
US20080261925A1 (en) 2008-10-23
EP2591769A3 (en) 2013-09-11
AU2007341940A1 (en) 2008-07-10
US20110195941A1 (en) 2011-08-11
EP2101727B1 (en) 2017-11-08
US20160235770A1 (en) 2016-08-18
EP2591769A2 (en) 2013-05-15
JP5840348B2 (ja) 2016-01-06
CA2674063A1 (en) 2008-07-10
US8404667B2 (en) 2013-03-26
EP2591769B1 (en) 2017-11-08
US20170326159A1 (en) 2017-11-16
NZ577962A (en) 2012-07-27
US9339509B2 (en) 2016-05-17
EP2101727A2 (en) 2009-09-23
JP2010514812A (ja) 2010-05-06
CA2674063C (en) 2016-01-19

Similar Documents

Publication Publication Date Title
MX2009007015A (es) Compuestos, composiciones, kits y metodos de uso para tratar oral y topicamente el acne y otras condiciones de la piel mediante administracion de un analogo de vitamina d que contiene 19-nor, con o sin un retinoide.
Beckenbach et al. Retinoid treatment of skin diseases
Krautheim et al. Acne: topical treatment
Krautheim et al. Transdermal penetration of topical drugs used in the treatment of acne
US20100286257A1 (en) Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
Rigopoulos et al. Comparison of topical retinoids in the treatment of acne
US20160175324A1 (en) Anti-acne compositions comprising bile acid-fatty acid conjugates
WO2013124479A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
Futoryan et al. Retinoids and the skin
WO2000049992A2 (en) USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS
JPH03141218A (ja) 糖質コルチコイド誘発皮膚萎縮症の逆転
US7736661B1 (en) Method of treating skin conditions
WO2009111688A3 (en) All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof
US20200397676A1 (en) Cosmetic compositions and methods of use
JP5791903B2 (ja) 皮膚および／または髪の外観を改善するための、光線とリパーゼにより生物学的に変換可能な化合物との組合せ
CA2762394C (en) Topical retinoid solutions
EP2838508A1 (en) Formulations and methods for treatment of acne and inflammatory skin conditions
US10022348B2 (en) Topical solution of isotretinoin
Kovtun et al. Retinoids in dermatology: functional activity and prospects of synthetic analogues
Archana et al. Retinoids-an overview of clinical applications in dermatology
CONS Retinol, Retinyl Esters, and Retinoic Acid
Anastassakis Retinoic Acid
Aranegui et al. Topical retinoids
WO2015023497A1 (en) Use of fatty acid to reduce skin irritation associated with retinoid therapy
WO2011152832A1 (en) Methods of use of nitroalkene compositions in dermatologic applications to prevent or treat skin aging

Legal Events

Date Code Title Description
FA Abandonment or withdrawal